efficacy and safety of ibandronic acid administered intravenously to juvenile arthritis patients with severe system osteoporosis
Article Quality & Performance Metrics
Readership in this journal
EmergingRanked #18 of 111 articles by views in Biocontrol science
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
Abstract
The article is dedicated to study of efficacy and safety of ibandronic acid administered intravenously to 25 patients suffering from juvenile arthritis and system osteoporosis. It was concluded that administration of 3 mg of ibandronate every 3 months during 76 weeks increase CTX, which indicates improvement of bone metabolism. During the treatment no subsequent vertebrae fractures have been registered. Increase in bone mass during the ibandronate therapy has been sufficient to allow endoprosthetic hip replacement in 7 patients.
Key words: child, juvenile arthritis, osteoporosis, treatment, biophosphates, ibandronic acid.
(Voprosy sovremennoi pediatrii — Current Pediatrics. — 2011; 10 (6): 83–88)
| Reference Key |
denisova2011voprosyefficacy
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;R.V. Denisova;E.I. Alexeeva;V.G. Pinelis;M.I. Bakanov;S.I. Valieva;T.M. Bzarova;K.B. Isaeva;S.Yu. Morev;G.V. Kuznetsova |
| Journal | Biocontrol science |
| Year | 2011 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.